Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta‑analysis

Liu,Zihan; He,Yonglai; Lian,Xiaojuan; Zou,Hong; Huang,Yalan; Wang,Ning; Hu,Jianming; Cui,Xiaobin; Zhao,Jin; Zhang,Wenjie; Gu,Wenyi; Pang,Lijuan; Qi,Yan

doi:10.3892/etm.2019.7906

Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta‑analysis

Authors:
- Zihan Liu
- Yonglai He
- Xiaojuan Lian
- Hong Zou
- Yalan Huang
- Ning Wang
- Jianming Hu
- Xiaobin Cui
- Jin Zhao
- Wenjie Zhang
- Wenyi Gu
- Lijuan Pang
- Yan Qi
View Affiliations

Affiliations: Department of Pathology, Shihezi University School of Medicine and The First Affiliated Hospital to Shihezi University School of Medicine, Shihezi, Xinjiang 832002, P.R. China, Department of Emergency, Jinshan Branch Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, P.R. China, Department of Blood Cancers, Jiangjin Central Hosptial of Chongqing, Chongqing 400042, P.R. China, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane QLD 4072, Australia
Published online on: August 16, 2019 https://doi.org/10.3892/etm.2019.7906
Pages: 3161-3171

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

E1A binding protein p300 (P300) is a member of the histone acetyltransferase family of transcriptional co‑activators, which are associated with various types of cancer. Numerous studies have evaluated the diagnostic value of P300, but their results are not consistent. Therefore, a clinical study and a meta‑analysis were performed in the present study to investigate the prognostic value of P300 expression in human malignant neoplasms. Immunohistochemical (IHC) analysis was used to assess P300 expression in 43 paraffin‑embedded primary synovial sarcoma (SS) samples. For the meta‑analysis, eligible studies published until January 21, 2018 were identified by searching the PubMed, EMBASE and Web of Science databases. The IHC analysis indicated a high P300 expression rate in 33.3% (10/30) of biphasic SS (BSSs) and in 60% (6/10) of monophasic fibrous SS tissues. In BSS, the expression rate was significantly higher in the epithelial component (80.0%, 24/30) than that in the spindle‑cell component (30.0%, 9/30; P<0.05). The meta‑analysis indicated that high expression of P300 was associated with poor overall survival (OS) in digestive system malignant neoplasms (HR=1.54, 95% CI: 1.20‑2.23), as well as with poor progression‑free survival, recurrence‑free survival and disease‑free survival combined (HR=1.84, 95% CI: 1.36‑2.47). Analysis of subgroups by ethnicity demonstrated that high expression of P300 was associated with poor OS in Asians (HR=1.72, 95% CI: 1.20‑2.47) but favourable OS in Caucasians (HR=0.59, 95% CI: 0.47‑0.73). Furthermore, high expression of P300 was associated with clinical stage [Relative Risk (RR)=1.30, 95% CI: 1.07‑1.58], lymph node metastasis (RR=1.30, 95% CI: 1.03‑1.64) and depth of invasion (RR=1.31, 95% CI: 1.07‑1.60). P300 expression may therefore be a useful biomarker for predicting patient prognosis in various types of human cancer.

View Figures

View References

1	Kundu TK, Palhan VB, Wang Z, An W, Cole PA and Roeder RG: Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol Cell. 6:551–561. 2000. View Article : Google Scholar : PubMed/NCBI
2	Vo N and Goodman RH: CREB-binding protein and p300 in transcriptional regulation. J Biol Chem. 276:13505–13508. 2001. View Article : Google Scholar : PubMed/NCBI
3	Huang WC and Chen CC: Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol. 25:6592–6602. 2005. View Article : Google Scholar : PubMed/NCBI
4	Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, Iwama T and Miyaki M: p300 gene alterations in colorectal and gastric carcinomas. Oncogene. 12:1565–1569. 1996.PubMed/NCBI
5	Wang L, Huang X, Chai Y, Zou L, Chedrawe M and Ding Y: Octreotide inhibits the proliferation of gastric cancer cells through P300-HAT activity and the interaction of ZAC and P300. Oncol Rep. 37:2041–2048. 2017. View Article : Google Scholar : PubMed/NCBI
6	Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, et al: Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 24:300–303. 2000. View Article : Google Scholar : PubMed/NCBI
7	Shikama N, Lee CW, France S, Delavaine L, Lyon J, Krstic-Demonacos M and La Thangue NB: A novel cofactor for p300 that regulates the p53 response. Mol Cell. 4:365–376. 1999. View Article : Google Scholar : PubMed/NCBI
8	Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL and Cai MY: High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med. 9:52011. View Article : Google Scholar : PubMed/NCBI
9	Isharwal SM, Miller MC, Marlow C, Makarov DV, Partin AW and Veltri RW: p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate. 68:1097–1104. 2008. View Article : Google Scholar : PubMed/NCBI
10	Xiao XS, Cai MY, Chen JW, Guan XY, Kung HF, Zeng YX and Xie D: High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis. Chin J Cancer Res. 23:201–207. 2011. View Article : Google Scholar : PubMed/NCBI
11	Chen YF, Luo RZ, Li Y, Cui BK, Song M, Yang AK and Chen WK: High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 270:1009–1017. 2013. View Article : Google Scholar : PubMed/NCBI
12	Qi Y, Wang CC, He YL, Zou H, Liu CX, Pang LJ, Hu JM, Jiang JF, Zhang WJ and Li F: The correlation between morphology and the expression of TGF-β signaling pathway proteins and epithelial-mesenchymal transition-related proteins in synovial sarcomas. Int J Clin Exp Pathol. 6:2787–2799. 2013.PubMed/NCBI
13	Greenwood DC: Meta-analysis of observational studies. Mod Methods Epidemiol. 173–189. 2012. View Article : Google Scholar
14	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
15	Chen MK, Cai MY, Luo RZ, Tian X, Liao QM, Zhang XY and Han JD: Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma. Br J Dermatol. 172:111–119. 2015. View Article : Google Scholar : PubMed/NCBI
16	Gao Y, Geng J, Hong X, Qi J, Teng Y, Yang Y, Qu D and Chen G: Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer. Int J Clin Exp Pathol. 7:760–767. 2014.PubMed/NCBI
17	Bhandaru M, Ardekani GS, Zhang G, Martinka M, McElwee KJ, Li G and Rotte A: A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. BMC Cancer. 14:3982014. View Article : Google Scholar : PubMed/NCBI
18	Zhang LH, Huang Q, Fan XS, Wu HY, Yang J and Feng AN: Clinicopathological significance of SIRT1 and p300/CBP expression in gastroesophageal junction (GEJ) cancer and the correlation with E-cadherin and MLH1. Pathol Res Pract. 209:611–617. 2013. View Article : Google Scholar : PubMed/NCBI
19	Rotte A, Bhandaru M, Cheng Y, Sjoestroem C, Martinka M and Li G: Decreased expression of nuclear p300 is associated with disease progression and worse prognosis of melanoma patients. PLoS One. 8:e754052013. View Article : Google Scholar : PubMed/NCBI
20	Huh JW, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, Lee WY and Chun H: Prognostic impact of p300 expression in patients with colorectal cancer. J Surg Oncol. 108:374–377. 2013. View Article : Google Scholar : PubMed/NCBI
21	Liao ZW, Zhou TC, Tan XJ, Song XL, Liu Y, Shi XY, Huang WJ, Du LL, Tu BJ and Lin XD: High expression of p300 is linked to aggressive features and poor prognosis of nasopharyngeal carcinoma. J Transl Med. 10:1102012. View Article : Google Scholar : PubMed/NCBI
22	Ono H, Basson MD and Ito H: P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. Oncotarget. 7:51301–51310. 2016. View Article : Google Scholar : PubMed/NCBI
23	Hou X, Li Y, Luo RZ, Fu JH, Zhang LJ and Yang HX: High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers. Eur J Surg Oncol. 38:523–530. 2012. View Article : Google Scholar : PubMed/NCBI
24	Li Y, Yang HX, Luo RZ, Zhang Y, Li M, Wang X and Jia WH: High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 91:1531–1538. 2011. View Article : Google Scholar : PubMed/NCBI
25	Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S and Kimura W: Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol. 60:1205–1210. 2007. View Article : Google Scholar : PubMed/NCBI
26	Qi Y, Wang N, Pang LJ, Zou H, Hu JM, Zhao J, Zhang J, Liu CX, Zhang WJ, Yuan XL and Li F: Identification of potential mutations and genomic alterations in the epithelial and spindle cell components of biphasic synovial sarcomas using a human exome SNP chip. BMC Med Genomics. 8:692015. View Article : Google Scholar : PubMed/NCBI
27	Liao ZW, Zhao L, Cai MY, Xi M, He LR, Yu F, Zhou TC and Liu MZ: P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line. Oncol Lett. 13:763–769. 2017. View Article : Google Scholar : PubMed/NCBI
28	Pifer PM, Farris JC, Thomas AL, Stoilov P, Denvir J, Smith DM and Frisch SM: Grainyhead-like 2 inhibits the coactivator p300, suppressing tubulogenesis and the epithelial-mesenchymal transition. Mol Biol Cell. 27:2479–2492. 2016. View Article : Google Scholar : PubMed/NCBI
29	Inagaki Y, Shiraki K, Sugimoto K, Yada T, Tameda M, Ogura S, Yamamoto N, Takei Y and Ito M: Epigenetic regulation of proliferation and invasion in hepatocellular carcinoma cells by CBP/p300 histone acetyltransferase activity. Int J Oncol. 48:533–540. 2016. View Article : Google Scholar : PubMed/NCBI
30	Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, Li YH, Wang LL and Yu L: A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One. 8:e554812013. View Article : Google Scholar : PubMed/NCBI
31	Ono H, Basson MD and Ito H: P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. Oncotarget. 7:51301–51310. 2016. View Article : Google Scholar : PubMed/NCBI
32	Dou YL, Lin JP, Liu FE, Wang LY, Shu HH, Jiang N, Xie Y and Duan Q: Midazolam inhibits the proliferation of human head and neck sqamous carcinoma cells by downregulating p300 expression. Tumour Biol. 35:7499–7504. 2014. View Article : Google Scholar : PubMed/NCBI
33	Mohammed SI, Springfield S and Das R: Role of epigenetics in cancer health disparities. Methods Mol Biol. 863:395–410. 2012. View Article : Google Scholar : PubMed/NCBI
34	Langevin SM and Kelsey KT: The fate is not always written in the genes: Epigenomics in epidemiologic studies. Environ Mol Mutagen. 54:533–541. 2013. View Article : Google Scholar : PubMed/NCBI
35	McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V, Deapen D and Ward E: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 57:190–205. 2007. View Article : Google Scholar : PubMed/NCBI
36	Chien C, Morimoto LM, Tom J and Li CI: Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer. 104:629–639. 2005. View Article : Google Scholar : PubMed/NCBI